Your browser doesn't support javascript.
loading
Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab.
Aira, Lazaro E; López-Requena, Alejandro; Fuentes, Dasha; Sánchez, Liset; Pérez, Teresita; Urquiza, Aleida; Bautista, Heber; Falcón, Leopoldina; Hernández, Patricia; Mazorra, Zaima.
Afiliação
  • Aira LE; Center of Molecular Immunology; Havana, Cuba.
  • López-Requena A; Center of Molecular Immunology; Havana, Cuba; Biotech Pharmaceutical Co. Ltd.; Beijing, China.
  • Fuentes D; National Center for Laboratory Animal Breeding; Havana, Cuba.
  • Sánchez L; Center of Molecular Immunology; Havana, Cuba.
  • Pérez T; Hermanos Ameijeiras Hospital; Havana, Cuba.
  • Urquiza A; Medical Surgical Research Center; Havana, Cuba.
  • Bautista H; Manuel Fajardo Hospital; Havana, Cuba.
  • Falcón L; Carlos Juan Finlay Hospital; Havana, Cuba.
  • Hernández P; Center of Molecular Immunology; Havana, Cuba.
  • Mazorra Z; Center of Molecular Immunology; Havana, Cuba.
MAbs ; 6(3): 783-93, 2014.
Article em En | MEDLINE | ID: mdl-24594862
Psoriasis is a chronic inflammatory disease with a prevalence of approximately 2-3% in the general population. The majority of diagnosed patients have plaque psoriasis, and about 20% have moderate-to-severe disease. Itolizumab, a new monoclonal antibody specific for the CD6 molecule mainly expressed on T lymphocytes, has demonstrated to inhibit in vitro ligand-induced proliferation and pro-inflammatory cytokine production. We assessed the immunological and histopathological effect of the antibody using clinical samples taken from 26 patients with moderate-to-severe psoriasis included in a clinical trial. The precursor frequency of lymphocytes activated with anti-CD2/CD3/CD28 beads, as well as the number of interferon (IFN)-γ-secreting T cells after stimulation, were measured at different time points of the study. Serum cytokine levels and anti-idiotypic antibody response to itolizumab were also evaluated. Additionally, lymphocyte infiltration and epidermis hyperplasia were studied in five patients. A significant reduction in T cell proliferation capacity and number of IFN-γ-producing T cells was found in treated patients. Serum levels of interleukin-6, tumor necrosis factor and IFN-γ showed an overall trend toward reduction. No anti-idiotypic antibody response was detected. A significant reduction in the epidermis hyperplasia was observed in analyzed patients. These results support the relevance of the CD6 molecule as a therapeutic target for the treatment of this disease.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Psoríase / Antígenos de Diferenciação de Linfócitos T / Antígenos CD / Anticorpos Monoclonais Humanizados Tipo de estudo: Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: MAbs Assunto da revista: ALERGIA E IMUNOLOGIA Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Cuba País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Psoríase / Antígenos de Diferenciação de Linfócitos T / Antígenos CD / Anticorpos Monoclonais Humanizados Tipo de estudo: Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: MAbs Assunto da revista: ALERGIA E IMUNOLOGIA Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Cuba País de publicação: Estados Unidos